Update of chronic hepatitis B

Hejun Yuan, William M. Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of review: We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010. Recent findings: It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at-risk populations. Seven medications have been approved to treat CHB in adults, but only four medications have been approved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an important treatment endpoint in HBeAg-positive patients. Durability of nucleoside analogue treatment-related HBeAg seroconversion is still questionable. Hepatitis B surface antigen (HBsAg) seroclearance has been achieved in some patients with antiviral therapy. HBsAg quantitation and kinetics is now being studied to determine its role in the natural history of CHB and whether these measures may predict future response to current antiviral therapy. Summary: Great advances have been made in understanding the HBeAg seroconversion durability. The clinical significance of serum HBsAg kinetics has been recognized in naive CHB patients and patients with antiviral therapy. More education programs are needed to improve the public awareness of the importance of CHB to the health of whole population.

Original languageEnglish (US)
Pages (from-to)217-223
Number of pages7
JournalCurrent Opinion in Gastroenterology
Volume27
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Chronic Hepatitis B
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Antiviral Agents
Therapeutics
Nucleosides
Education
Health
Serum
Population

Keywords

  • antiviral therapy
  • chronic hepatitis B

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Update of chronic hepatitis B. / Yuan, Hejun; Lee, William M.

In: Current Opinion in Gastroenterology, Vol. 27, No. 3, 05.2011, p. 217-223.

Research output: Contribution to journalArticle

Yuan, Hejun ; Lee, William M. / Update of chronic hepatitis B. In: Current Opinion in Gastroenterology. 2011 ; Vol. 27, No. 3. pp. 217-223.
@article{433a04c8b4a24e329f6bda29e61f6320,
title = "Update of chronic hepatitis B",
abstract = "Purpose of review: We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010. Recent findings: It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at-risk populations. Seven medications have been approved to treat CHB in adults, but only four medications have been approved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an important treatment endpoint in HBeAg-positive patients. Durability of nucleoside analogue treatment-related HBeAg seroconversion is still questionable. Hepatitis B surface antigen (HBsAg) seroclearance has been achieved in some patients with antiviral therapy. HBsAg quantitation and kinetics is now being studied to determine its role in the natural history of CHB and whether these measures may predict future response to current antiviral therapy. Summary: Great advances have been made in understanding the HBeAg seroconversion durability. The clinical significance of serum HBsAg kinetics has been recognized in naive CHB patients and patients with antiviral therapy. More education programs are needed to improve the public awareness of the importance of CHB to the health of whole population.",
keywords = "antiviral therapy, chronic hepatitis B",
author = "Hejun Yuan and Lee, {William M.}",
year = "2011",
month = "5",
doi = "10.1097/MOG.0b013e32834595b5",
language = "English (US)",
volume = "27",
pages = "217--223",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Update of chronic hepatitis B

AU - Yuan, Hejun

AU - Lee, William M.

PY - 2011/5

Y1 - 2011/5

N2 - Purpose of review: We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010. Recent findings: It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at-risk populations. Seven medications have been approved to treat CHB in adults, but only four medications have been approved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an important treatment endpoint in HBeAg-positive patients. Durability of nucleoside analogue treatment-related HBeAg seroconversion is still questionable. Hepatitis B surface antigen (HBsAg) seroclearance has been achieved in some patients with antiviral therapy. HBsAg quantitation and kinetics is now being studied to determine its role in the natural history of CHB and whether these measures may predict future response to current antiviral therapy. Summary: Great advances have been made in understanding the HBeAg seroconversion durability. The clinical significance of serum HBsAg kinetics has been recognized in naive CHB patients and patients with antiviral therapy. More education programs are needed to improve the public awareness of the importance of CHB to the health of whole population.

AB - Purpose of review: We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010. Recent findings: It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at-risk populations. Seven medications have been approved to treat CHB in adults, but only four medications have been approved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an important treatment endpoint in HBeAg-positive patients. Durability of nucleoside analogue treatment-related HBeAg seroconversion is still questionable. Hepatitis B surface antigen (HBsAg) seroclearance has been achieved in some patients with antiviral therapy. HBsAg quantitation and kinetics is now being studied to determine its role in the natural history of CHB and whether these measures may predict future response to current antiviral therapy. Summary: Great advances have been made in understanding the HBeAg seroconversion durability. The clinical significance of serum HBsAg kinetics has been recognized in naive CHB patients and patients with antiviral therapy. More education programs are needed to improve the public awareness of the importance of CHB to the health of whole population.

KW - antiviral therapy

KW - chronic hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=79955068632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955068632&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32834595b5

DO - 10.1097/MOG.0b013e32834595b5

M3 - Article

C2 - 21423004

AN - SCOPUS:79955068632

VL - 27

SP - 217

EP - 223

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -